Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at ...
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Cancers, Gardasil, Hpv, Human Papillomavirus, Intraepithelial Neoplasia, Men Who Have Sex With Men, Merck, Merck Co, Merck Co Inc, Old Men, Phase Iii, Sex With Men
